Stock Quote Notification for Eli Lilly and Company

Eli Lilly and sent this email to their subscribers on September 12, 2024.

Company: Eli Lilly and Company
Ticker: LLY
Exchange: NYSE
Last Trade: $935.02
Change: 14.13
% Change: +1.53%
Volume: 2,510,131
Day's High: $937.62
Day's Low: $918.63
Previous Close: $920.89

Text-only version of this email

Eli Lilly and Company Company: Eli Lilly and Company Ticker: LLY Exchange: NYSE Last Trade: $935.02 Change: 14.13 % Change: +1.53% Volume: 2,510,131 Day's High: $937.62 Day's Low: $918.63 Previous Close: $920.89

Show all

The Latest Emails Sent By Eli Lilly and

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase